SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, Auger08, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 2/27/2015 9:39:44 PM - Followers: 632 - Board type: Free - Posts Today: 0

 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »

Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.


Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.




Press Releases






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#81673   You are right... Think about all the people ddombrow 02/27/15 09:39:44 PM
#81672   Integrating the area above or below the closing Captain Kirk 02/27/15 09:32:54 PM
#81671   If u look at the last 10 trading homeslice10 02/27/15 09:14:51 PM
#81670   Actually the largest sell of the day was Captain Kirk 02/27/15 08:15:30 PM
#81669   Popped strong positive had to be pulled down homeslice10 02/27/15 08:10:32 PM
#81668   Closed solid red on higher than avg volume Captain Kirk 02/27/15 08:05:16 PM
#81667   Sooo "Oh gosh, solid RED selling?" what does Trader Joey 02/27/15 06:52:54 PM
#81664   CK some things that you bring to the SMD2014 02/27/15 02:49:21 PM
#81661   Wrong again homeslice10 02/27/15 01:11:39 PM
#81657   I have TDAmeritrade and my screen says NASDAQ Mushroom 02/27/15 11:36:06 AM
#81655   Maybe this is why OCAT withdrew the offering: SRSKinvested 02/27/15 11:28:16 AM
#81654   I agree with that also, and to be elysse1kittycat 02/27/15 10:40:19 AM
#81653   No reason to not do both. OCAT is es1 02/27/15 10:28:24 AM
#81652   Oh gosh, solid RED selling? Captain Kirk 02/27/15 10:22:46 AM
#81651   TD ameritrade shows NASDAQ calm61 02/27/15 10:10:44 AM
#81650   TDAmeritrade is still showing OCAT as being on blaydonracer 02/27/15 10:05:23 AM
#81649   I agree with you also. elysse1kittycat 02/27/15 10:01:50 AM
#81648   I agree with that. I should say I es1 02/27/15 09:44:33 AM
#81647   This may not be a perfect comparison but elysse1kittycat 02/27/15 09:27:15 AM
#81646  Restored Uh, all except that MSFT was PROFITABLE FROM Captain Kirk 02/27/15 09:18:40 AM
#81645   That is simply because an uplist does not es1 02/27/15 09:18:18 AM
#81644   HEY OCAT PEEPS TODAY IS FRIDAY AND THAT sports guy 02/27/15 08:54:27 AM
#81643   Sports like Microsoft when people were saying PC's Shiskabill 02/27/15 08:49:30 AM
#81642   There and back 260,000 miles Gastrodamas 02/27/15 08:37:54 AM
#81641   To the MOON OCATA, which reminds me of Gastrodamas 02/27/15 08:37:12 AM
#81640   Probaly carried with us the same lice,ticks, blood Gastrodamas 02/27/15 08:31:59 AM
#81639   Nice write up. Honest Gastrodamas 02/27/15 08:28:23 AM
#81638   As of 817 I show pre-market pps as Gastrodamas 02/27/15 08:19:55 AM
#81637   So good to be here so long and sports guy 02/27/15 07:34:04 AM
#81636   Very glad that I am part of this calm61 02/26/15 11:20:41 PM
#81635   Ocata Therapeutics To Trade On Nasdaq Global Market: lasers 02/26/15 10:57:49 PM
#81634   Yeah typo, 5 Cents. You're correct. Great Captain Kirk 02/26/15 10:11:23 PM
#81633   I am of the same opinion. It is lasers 02/26/15 10:04:43 PM
#81632   Well CK, I believe $.05 is NOT 5/100ths kenny33 02/26/15 09:56:00 PM
#81631   I have read excerpts of some of Dr. elysse1kittycat 02/26/15 09:42:13 PM
#81630   usdollars76 Welcome to ihub $OCAT MB. We can lasers 02/26/15 09:01:44 PM
#81629   New to IHUB. I have been in this usdollars76 02/26/15 08:53:46 PM
#81628   I dont give a plug nickel. Glad to Gastrodamas 02/26/15 08:38:06 PM
#81627   Quote, "OCAT finished green...even after someone tired to Captain Kirk 02/26/15 07:14:28 PM
#81626   This will be lucky to even close green Trader Joey 02/26/15 06:38:10 PM
#81625 andyshow 02/26/15 05:02:16 PM
#81624   I think the board thinks there will be guy3 02/26/15 03:54:04 PM
#81623   north40000 Once WET AMD has set in it lasers 02/26/15 03:43:19 PM
#81622   Actually this is a disappointing day considering it smokey 02/26/15 03:42:49 PM
#81621   We should soon see a very bullish Seeking farviewhill 02/26/15 03:39:59 PM
#81620   Looks like the NASDAQ pro short desks and Captain Kirk 02/26/15 03:37:14 PM
#81619   The more sellers the faster we move up homeslice10 02/26/15 03:26:47 PM
#81618   Can wet AMD arise other than via dry north40000 02/26/15 03:16:43 PM
#81617   good points. $OCAT is moving forward. Lets poke guy3 02/26/15 02:02:38 PM
#81616   IMO additional $OCAT info coming as the 10-K lasers 02/26/15 01:42:10 PM